Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.65 |
| ▸ | NR3C2 | P08235 | 17/20 | 0.64 |
| ▸ | PARP1 | P09874 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 6/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861248 | 0.86 | NR3C2 (0.57) | MMP12NR3C2PARP1PGR | |
| SCHEMBL30053776 | 0.86 | NR3C2 (0.57) | MMP12NR3C2PARP1PGR | |
| SCHEMBL15964653 | 0.83 | NR3C2 (0.49) | MMP12NR3C2PARP1PGRNR3C1 | |
| SCHEMBL10510154 | 0.80 | NR3C2 (0.48) | MMP12NR3C2PGRNR3C1 | |
| SCHEMBL7132 | 0.80 | NR3C2 (0.72) | MMP12NR3C2PARP1PGR | |
| SCHEMBL4287012 | 0.80 | NR3C2 (0.79) | NR3C2PGRNR3C1 | |
| SCHEMBL25358350 | 0.79 | NR3C2 (0.60) | MMP12NR3C2PARP1PGRNR3C1 | |
| SCHEMBL30193973 | 0.79 | NR3C2 (0.60) | MMP12NR3C2PARP1PGRNR3C1 | |
| SCHEMBL4293838 | 0.79 | NR3C2 (1.00) | NR3C2PGRNR3C1 | |
| SCHEMBL4293556 | 0.79 | NR3C2 (0.90) | NR3C2PGRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024170772-A1 | EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA | MIM NEUROSCIENCES AB (SE) | 2024-08-22 | — | — | WO | claimed |
| WO-2024170772-A1 | EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA | MIM NEUROSCIENCES AB (SE) | 2024-08-22 | — | — | WO | disclosed |
| WO-2023272720-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS | Ascletis BioScience Co., Ltd (CN) | 2023-01-05 | — | — | WO | disclosed |
| US-10851215-B2 | Graphene-augmented composite materials | THE BOEING COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3661990-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M Innovative Properties Company (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20190338087-A1 | GRAPHENE-AUGMENTED COMPOSITE MATERIALS | THE BOEING COMPANY (US) | 2019-11-07 | — | — | US | disclosed |
| US-10400075-B2 | Graphene-augmented composite materials | THE BOEING COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2019027746-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20180223055-A1 | GRAPHENE-AUGMENTED COMPOSITE MATERIALS | THE BOEING COMPANY (US) | 2018-08-09 | — | — | US | disclosed |
| US-9963562-B2 | Graphene-augmented composite materials | THE BOEING COMPANY (US) | 2018-05-08 | — | — | US | disclosed |
| EP-0625982-B1 | 4-OXO- AND 4H-IMIDAZO(5,1-C)(1,4)BENZOXAZINES USEFUL AS BENZODIAZEPINE RECEPTOR-BINDING AGENTS | UPJOHN CO (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001085673-A1 | PHENYL-SUBSTITUTED 2-ENAMINO-KETO NITRILES | BAYER CROPSCIENCE AG (DE) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001060797-A1 | PHENYL-SUBSTITUTED HETEROCYCLIC ENAMINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-08-23 | — | — | WO | disclosed |
| US-5610158-A | ANXIOLYTIC AGENTS, SEDATIVES | THE UPJOHN COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0625982-A1 | 4-OXO- AND 4H-IMIDAZO(5,1-C)(1,4)BENZOXAZINES USEFUL AS BENZODIAZEPINE RECEPTOR-BINDING AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993016082-A1 | 4-OXO- AND 4H-IMIDAZO(5,1-C)(1,4)BENZOXAZINES USEFUL AS BENZODIAZEPINE RECEPTOR-BINDING AGENTS | THE UPJOHN COMPANY (US) | 1993-08-19 | — | — | WO | disclosed |
| EP-0170191-B1 | TETRAHYDROPHTALIMIDES, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-11-23 | — | — | EP | disclosed |
| EP-0162776-B1 | HETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS USEFUL AS ALDOSE REDUCTASE INHIBITORS CONTAINING THEM | LABORATOIRES UPSA (FR) | 1989-04-19 | — | — | EP | disclosed |
| US-4755509-A | Heterocyclic aldose reductase inhibitors and methods of using them | Carbipem (FR) | 1988-07-05 | — | — | US | disclosed |
| EP-0162776-A2 | Heterocyclic derivatives, process for their preparation and medicaments useful as aldose reductase inhibitors containing them | LABORATOIRES UPSA (FR) | 1985-11-27 | — | — | EP | disclosed |